A-share market movement | The Hantavirus outbreak draws attention! The virus prevention and treatment sector collectively surged, with Wantai Biotech up 9% and BGI Genomics rising over 5%.

Gelonghui, May 11 | Virus prevention and control concept stocks collectively rose in the A-share market. Among them, Walvax Biotech surged 19%, Capricorn Bio-Tech increased by over 15%, Daan Gene hit a 10% price limit, Wantai BioPharm gained 9%, Kangtai Biological Products rose over 8%, Zhifei Biological Products climbed 7%, and Frontier Biopharma-U, Probiotics Pharmaceuticals, CanSino Biologics, Wondfo Biotech, and Kanghua Biological Products increased by over 6%. Additionally, Jindike Biologics, BGI Group, Sichuan Maik Biotechnology, and TopRim Pharmaceuticals saw gains exceeding 5%. In terms of news, the cruise ship 'Hondeus' recently reported an outbreak of Hantavirus. Furthermore, a fatal case of Hantavirus was reported in Taipei City, Taiwan, related to infections carried by rats, drawing significant public attention.

Gelonghui FinanceMay 11 13:35

KANGTAI BIOLOGICAL(300601): R&D PIPELINE CONTINUES TO PROGRESS; OVERSEAS BUSINESS ACHIEVES SIGNIFICANT GROWTH

Key takeaway: The company released its 2025 annual report and 1Q26 results.

CSC Financial Co., Ltd.May 8 20:36

Kangtai Bio (300601): Continuous advancement in the R&D pipeline, overseas business achieves rapid growth.

Key insights: The company released its 2025 annual report and Q1 2026 earnings report. In 2025, sales revenue remained robust, with new products such as the human diploid rabies vaccine and varicella vaccine continuing to gain market traction. Multiple vaccine products received regulatory approval for market entry. Q1 2026 was impacted by R&D expenses.

CSC Financial Co., Ltd.May 3 09:02

Kangtai Bio (300601): Stable Revenue Growth with a Rich Product Pipeline

Key investment highlights: Steady growth in revenue, with continued pressure on profits. In 2025, the company achieved operating revenue of 2.673 billion yuan (an increase of 0.81% year-on-year), net profit attributable to shareholders of 70 million yuan (a decrease of 65.12% year-on-year), and non-recurring net profit attributable to shareholders...

Donghai SecuritiesApr 28 00:00

Shenzhen Kangtai Biological Products Co., Ltd. Just Missed Earnings - But Analysts Have Updated Their Models

Simply Wall StApr 24 07:27

Kangtai Bio (300601): Stable revenue but pressured profits; anticipation for R&D progress

The company announced revenue, net profit attributable to shareholders, and non-recurring net profit of RMB 2.67 billion, RMB 0.7 billion, and RMB 0.7 billion respectively for 2025 (+1%/-65%/-70% year-on-year). The decline in profits was mainly due to the adjustment of the DTP immunization program affecting the tetravalent vaccine and operating costs.

Huatai SecuritiesApr 23 00:00